Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma. (2017)

• Record Type: Journal Article
• Authors: Zarogoulidis, Paul; Huang, Haidong; Tsiouda, Theodora; Sardeli, Chrysa; Trakada, Georgia; Veletza, Lemonia; Kallianos, Anastasios; Kosmidis, Christoforos; Rapti, Aggeliki; Papaemmanouil, Liana; Hatzibougias, Dimitrios; Drougas, Dimitrios; Bai, Chong; Hohenforst-Schmidt, Wolfgang
• Is Part Of: Respiratory medicine case reports. Volume 22(2017)
• Page Start: 283
• Page End: 286
• Publication Date: 2017
• Subjects: NSCLC -- Nivolumab -- EBUS -- Adenocarcinoma; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2017.10.006
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and methods of diagnostic prevention. In the past ten years several targeted therapies have been introduced or explored. Tyrosine kinase inhibitors and immunotherapy are currently considered the most effective and safe therapies in comparison to the non-specific cytotoxic agents. Regarding tyrosine kinase inhibitors the adverse effects have been fully explored, however; on the other hand for immunotherapy there are still several issues to be clarified. We report a rare case of a patient with lung cancer adenocarcinoma who developed vitiligo throughout his body after nivolumab administration.